Related Experiment Video
Updated: Mar 8, 2026
A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Clinical characteristics, healthcare costs, and resource utilization in hepatitis C vary by genotype
Alyssa Goolsby Hunter1, Lisa Rosenblatt2, Chad Patel2
1a HEOR, Optum , Eden Prairie , USA.
Insights
Hepatitis C virus (HCV) genotype 3 is linked to more severe liver disease and higher healthcare costs. Early treatment is crucial for all patients, especially those with HCV genotype 3.
Area of Science:
- Hepatology
- Infectious Diseases
- Health Economics
Background:
- Hepatitis C virus (HCV) infects approximately 3 million people in the US.
- HCV genotypes influence disease progression and treatment outcomes.
- Limited understanding of genotype-specific impacts on liver disease, healthcare utilization, and costs.
Purpose of the Study:
- To investigate the association between HCV genotypes and liver disease progression.
- To analyze healthcare resource utilization (HCRU) and costs based on HCV genotype.
- To explore the relationship between HCV genotypes, comorbidities, and disease severity.
Main Methods:
- Retrospective study using healthcare claims data from a large US health plan.
- Included 10,331 patients with chronic hepatitis C (CHC).
- Linked laboratory data for HCV genotype and liver disease severity assessment.
Main Results:
- HCV genotype 3 (GT3) patients showed higher rates of liver-related comorbidities and advanced liver disease.
- HCV genotype 2 (GT2) patients had lower HCRU and costs.
- HCV genotype 1 (GT1) patients incurred the highest total all-cause costs; GT3 was linked to more advanced disease than GT1.
Conclusions:
- Liver disease progression and severity differ significantly by HCV genotype.
- Patients with GT3 exhibit more severe liver disease.
- Effective HCV treatment is vital for all, particularly high-risk GT3 patients.
Background:
In the United States, approximately 3 million people are infected with hepatitis C virus (HCV). Genotypes of HCV variably affect disease progression and treatment response. However, the relationships between HCV genotypes and liver disease progression, healthcare resource utilization, and healthcare costs have not been fully explored.
Research Design And Methods:
In this retrospective study of patients with chronic hepatitis C (CHC), healthcare claims from a large US health plan were used to collect data on patient demographic and clinical characteristics.
Main Outcome Measures:
Main outcome measures include healthcare resource utilization (HCRU) and healthcare costs. Linked laboratory data provided genotype and select measures to determine liver disease severity.
Results:
The sample (mean age 50.6 years, 63.5% male) included 10,331 patients, of whom 79.1% had genotype (GT)1, 12.8% had GT2, and 8.1% had GT3. Descriptive analyses demonstrated variation by HCV genotype in liver and non-liver related comorbidities, liver disease severity, and healthcare costs. The highest percentage of patients with liver-related comorbidities and advanced liver disease was found among those with GT3. Meanwhile, patients with GT2 had lower HCRU and the lowest costs, and patients with GT1 had the highest total all-cause costs. These differences may reflect differing rates of non-liver-related comorbidities and all-cause care. Multivariable analyses showed that genotype was a significant predictor of costs and liver disease severity: compared with patients having GT1, those with GT3 were significantly more likely to have advanced liver disease. Patients with GT2 were significantly less likely to have advanced disease and more likely to have lower all-cause costs.
Limitations:
Results may not be generalizable to patients outside the represented commercial insurance plans, and analysis of a prevalent population may underestimate HCRU and costs relative to a sample of treated patients.
Conclusions:
These results suggest that liver disease progression varies by genotype and that CHC patients with GT3 appear to have more severe liver disease. These findings highlight the importance of effective HCV treatment for all patients and support guidelines for treatment of high-risk patients, including those with GT3.
Related Concept Videos
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
01:16Hepatic Drug Excretion: Influencing Factors
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:14Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug